{
    "clinical_study": {
        "@rank": "124537", 
        "arm_group": {
            "arm_group_label": "MSC2156119J", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and\n      pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced\n      hepatocellular carcinoma (HCC) with child Pugh Class A liver function who have failed\n      sorafenib treatment."
        }, 
        "brief_title": "c-Met Second-Line Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed HCC\n\n          -  Child Pugh Class A liver function score\n\n          -  For Phase 2 only: MET+ status\n\n          -  Male or female, 18 years of age or older\n\n          -  Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors\n             (RECIST) version 1.1\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (inclusive)\n\n          -  Availability of a pretreatment tumor biopsy (excluding fine needle aspiration and\n             cytology samples) taken after the subject has discontinued sorafenib and within 28\n             days before the day of first dosing with MSC2156119J. From the pretreatment biopsy\n             either a formalin-fixed (formalin fixation is mandatory) paraffin-embedded block with\n             tumor tissue (preferred) or at least 15 unstained slides must be sent to the central\n             laboratory prior to enrollment. An associated pathology report must also be sent with\n             the sample\n\n          -  Previously treated with sorafenib for greater than or equal to 4 weeks and\n             discontinued sorafenib treatment at least 14 days prior to Day 1 due to either\n             intolerance or radiographic progression\n\n          -  Signed and dated informed consent indicating that the subject (or legally acceptable\n             representative if applicable by local laws) has been informed of all the pertinent\n             aspects of the trial prior to enrollment\n\n          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory\n             tests and other trial procedures\n\n          -  Life expectancy of at least 3 months as judged by the investigator\n\n        Exclusion Criteria:\n\n          -  Prior systemic anticancer treatment for advanced HCC (except for sorafenib as\n             described in the inclusion criteria)\n\n          -  Prior treatment with any agent targeting the hepatocyte growth factor (HGF)/c-Met\n             pathway\n\n          -  Local-regional therapy within 4 weeks before Day 1\n\n          -  Impaired cardiac function\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115373", 
            "org_study_id": "EMR 200095_005", 
            "secondary_id": "2013-002053-30"
        }, 
        "intervention": {
            "arm_group_label": "MSC2156119J", 
            "description": "MSC2156119J tablet will be administered in a total dose of 300 to 500 milligram (mg) orally once daily for repeated 21-day cycles until disease progression, intolerable toxicity, death, or withdrawal from treatment.", 
            "intervention_name": "MSC2156119J", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatocellular Carcinoma", 
            "c-Met inhibitor", 
            "Phase 1b", 
            "Sorafenib", 
            "MSC2156119J"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "contact": {
                "email": "service@merckgroup.com", 
                "phone": "+49-6151-72-5200"
            }, 
            "facility": {
                "address": {
                    "city": "Darmstadt", 
                    "country": "Germany"
                }, 
                "name": "Please contact the Merck KGaA Communication Center located in"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects With MET+ Advanced Hepatocellular Carcinoma With Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck KGaA", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Italy: The Italian Medicines Agency"
            ]
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Dose limiting toxicities (DLTs) occurring in Cycle 1", 
            "safety_issue": "Yes", 
            "time_frame": "up to Day 21 of Cycle 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115373"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to Progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Time from first study drug administration to the date of first occurrence of radiological progressive disease (PD) assessed on Day 1 of Cycles 3, 5, 7, 9, 11, 13 thereafter every 4 cycles up to 12 months after last subject's first dose"
            }, 
            {
                "measure": "Progression free survival (PFS) according to RECIST version 1.1 and modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC", 
                "safety_issue": "No", 
                "time_frame": "Time from first study drug administration to either first occurrence of radiological PD or death due to any cause within 12 weeks of the last tumor assessment or up to 12 months after last subject's first dose, whichever occurs first"
            }, 
            {
                "measure": "Time-to-symptomatic progression according to RECIST version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Time from first study drug administration to date of deterioration of symptoms or deterioration to Eastern Cooperative Oncology Group (ECOG) performance score 4 or death or up to 12 months  after last subject's first dose whichever occurs first"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Time from first study drug administration until death or up to 12 months after last subject's first dose whichever occurs first"
            }, 
            {
                "measure": "Best overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Time from first study drug administration until first occurrence of radiological PD assesses on Day 1 of Cycles 3, 5, 7, 9, 11, 13 thereafter every 4 cycles up to 12 months after last subject's first dose"
            }, 
            {
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "Time from first study drug administration until first occurrence of radiological PD assessed on Day 1 of Cycles 3, 5, 7, 9, 11, 13 thereafter every 4 cycles up to 12 months after last subject's first dose"
            }, 
            {
                "measure": "Biological response rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 21 of Cycle 2"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}